Dear Editor,

We read with interest a recent research by Chen and colleagues \[[@CR1]\] reporting on the clinical and mutation profiles of pediatric patients with RASopathy-associated hypertrophic cardiomyopathy (HCM). In this manuscript, the authors described the mutation spectrum causally linked to Noonan syndrome (NS) (MIM PS163950) and clinically related disorders, and the associated clinical outcome, based on a pediatric cohort of 47 affected subjects. An exhaustive genotype-phenotype correlation was reported. Particularly, the data allowed the authors to emphasize further the relevant contribution of the concomitant occurrence of congenital cardiac defects (CHDs) and left ventricular outflow tract obstruction (LVOTO) to the worse outcome of these patients. The authors also reported that patients with a diagnosis of NS based on clinical criteria and carrying two specific missense mutations in *PTPN11* (c1417A \> C, p.Q506P; c1528C \> G, p.Q510E) showed an early-onset presentation of HCM and a worse clinical outcome. Indeed, out of this subgroup of eleven patients, three of them (p.Q506P, *N* = 1; p.Q510E, *N* = 2) died within 6 months from birth.

We agree with Chen and colleagues that the co-occurrence of HCM and CHDs is generally associated to a worse outcome in patients with RASopathies. Indeed, these patients may show a rapid progression of HCM and this can lead to early cardiac failure. These data are also in line with other recently published studies \[[@CR2]--[@CR4]\]. In particular, our experience confirms that a worse clinical outcome is strictly closed to complex cardiac surgery \[[@CR2]\]. However, we would point out that the biochemical/functional behavior of *PTPN11* mutations at codons 510 (including c.1528C \> G) and 506 is drastically different from what observed for NS-causing *PTPN11* mutations. Specifically, the former cause defective protein phosphatase activity and differentially affect intracellular signaling \[[@CR5]--[@CR7]\]. Consistent with their distinctive consequences on SHP2 function and signal transduction, these mutations do not cause NS but underlie Noonan syndrome with multiple lentigines (NSML), previously known as LEOPARD syndrome (MIM PS151100), a disorder similar but distinct from NS. NSML-associated *PTPN11* mutations cluster within or close to the active site of the phosphatase, which explains their dramatic impact on phosphatase activity when compared with wild-type SHP2 and NS-causing *PTPN11* mutations \[[@CR5], [@CR8], [@CR9]\]. It should be noted that the presence of cutaneous manifestations as café-au-lait spots and multiple lentigines, which represent a distinctive feature of NSML, develop with age and do not generally occur in infancy. Based on this consideration, the absence of lentigines during infancy should not be used to exclude a diagnosis of NSML. HCM is an additional common complication of NSML. Differently from what reported by Chen and colleagues \[[@CR1]\], it is now well-established, and also in line with previous reports \[[@CR10]\], that c.1528C \> G (p.Q510E) in *PTPN11* is strictly associated to NSML. Review of published cases carrying the c.1528C \> G missense change documents that most of the patients have a clinical diagnosis of NSML syndrome (Table [1](#Tab1){ref-type="table"}) \[[@CR11]--[@CR14]\]. Notably, two among the three reported patients classified as having NS presented with HCM associated with deafness, a clinical feature characteristic for NSML (Table [1](#Tab1){ref-type="table"}) \[[@CR15]--[@CR17]\]. In regard to c.1529A \> C and c. 1530 G \> C, also involving codon 510 of *PTPN11*, it should be noted that all of them have been reported in patients diagnosed as having NSML syndrome (Table [1](#Tab1){ref-type="table"}) \[[@CR18]--[@CR21]\].Table 1Literature reports of patients carrying mutation at codon 510 of *PTPN11* geneMutationAge at observationReported clinical diagnosisClinical features specific for NS-MLReferencec.1529A \> C; p.Q510PAdultNS-MLLentiginesKeren et al., 2004c.1529A \> C; p.Q510P12 yearsNS-MLDeafnessLentiginesCafé-au-lait spotsHeart defect and ECG anomaliesKeren et al., 2004c.1529A \> C; p.Q510P25 yearsNS-MLDeafnessLentiginesCafé-au-lait spotsPVSKeren et al., 2004c.1528C \> G; p.Q510E14 monthsNSHCMDeafnessTakahashi et al., 2005c.1529A \> C; p.Q510PAdultNS-MLLentiginesKalidas et al., 2005c.1529A \> C; p.Q510PAdultNS-MLDeafnessLentiginesKalidas et al., 2005c.1529A \> C; p.Q510P1 yearNS-MLPVS, ASD, ECG anomaliesKalidas et al., 2005c.1528C \> G; p.Q510E2 yearsNS-MLHCMCafé-au lait spotsLentiginesDigilio et al., 2006c.1528C \> G; p.Q510E2 yearsNS-MLHCMCafé-au-lait spotsDigilio et al., 2006c.1528C \> G; p.Q510E2 monthsNSHCMFaienza et al., 2009c.1528C \> G; p.Q510E37 yearsNS-MLHCMLentiginesDeafnessLehmann et al., 2009c.1528C \> G; p.Q510E5 yearsNSHCM, PVSDeafnessDerbent et al., 2010c.1529A \> C; p.Q510P4 yearsNS or NS-MLCafé-au-lait spotBrasil et al., 2010c.1528C \> G; p.Q510EinfantNS-MLHCMGanigara et al., 2011c. 1530 G \> C; p.Q510H38 yearsNS-MLHCM, PVS, ASDLentiginesCafe-au-lait spotsWakabayashi et al., 2011c.1528C \> G; p.Q510E20 monthsNS-MLHCMDeafnessHahn et al., 2015*ASD* atrial septal defect, *ECG* electrocardiogram, *HCM* hypertrophic cardiomyopathy, *ML* multiple lentigines, *NS* Noonan syndrome, *PVS* pulmonary valve stenosis

While NS and NSML are genetic conditions with overlapping features, and clinicians experienced with these syndromes are aware of the difficulty in discriminating between these two disorders particularly in the first years of age \[[@CR11], [@CR22]\], we firmly believe that it is important to properly discriminate NSML from NS to allow a more effective patient management and a future personalized pharmacological treatment of the evolutive complications in these patients. Indeed, it is important to consider that different mechanisms of disease have been demonstrated to be associated with the two classes of *PTPN11* mutations underlying NS and NSML. On one hand, we have hyperactive mutants promoting upregulation of MAPK signaling (NS-causing mutations), which can effectively be controlled by the use of inhibitors of signal transducers functioning in this cascade (e.g., MEK1 inhibitors) \[[@CR23], [@CR24]\]. On the other hand, we have hypomorphic mutants that result in enhanced signal flow through the PI3K-AKT-MTOR pathway (NSML-causing mutations). In this case, inhibitors targeting this specific cascade (e.g., AKT inhibitors, rapamycin analogs) are required to counterbalance and treat evolutive complications of NSML, including HCM \[[@CR14], [@CR25], [@CR26]\]. On this argument, Wang et al. \[[@CR26]\] reported an in vivo study suggesting that the AKT inhibitor ARQ 092 may be a promising novel therapy for treatment of hypertrophy in NSML patients. Additionally, Hahn and colleagues \[[@CR14]\] reported the effects of treatment with a rapamycin analog in an infant with NSML and severe HCM.

In summary, we should avoid the misleading causative association between NSML-causing *PTPN11* mutations and NS, based on the diverse impact of these mutations on SHP2 function and intracellular signaling dysregulation, and their consequent significance in terms of patient management and future personalized therapeutic options.

CHDs

:   Congenital cardiac defects

HCM

:   Hypertrophic cardiomyopathy

LVOTO

:   Left ventricular outflow tract obstruction

NS

:   Noonan syndrome

NSML

:   Noonan Syndrome with Multiple Lentigines
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